Eli Lilly's Oral Weight-Loss Drug Foundayo Approved in the UK, Marking First European Regulatory Green Light
Nashnova编辑部
Eli Lilly's oral weight-loss drug Foundayo has won UK regulatory approval, its first in Europe; this puts two oral GLP-1 drugs on the same market just two months after Novo Nordisk's oral Wegovy cleared the same hurdle.
What is Foundayo, and how does it differ from Wegovy?
Foundayo's active ingredient is orforglipron, a single-target GLP-1 agonist — a drug that mimics a gut hormone to make you feel full sooner.
Oral Wegovy's active ingredient is semaglutide, the same GLP-1 class. The two are direct competitors in the same lane.
Lilly's injectable Zepbound uses tirzepatide, a dual-target drug — a different product from Foundayo entirely.
Why does the UK approval matter?
This is Foundayo's first regulatory clearance anywhere in Europe, coming roughly two months after oral Wegovy's UK approval.
This means → the UK market now has two oral GLP-1 weight-loss options, shifting the oral lane from a monopoly to head-to-head competition.
For Lilly, opening Europe is a critical step in closing Foundayo's revenue gap with Wegovy.
How is it selling so far?
Lilly's latest earnings show Foundayo posted $98 million in quarterly revenue, below the analyst consensus of $103 million.
The company acknowledged brand awareness remains low and is stepping up marketing.
FactSet consensus projects Foundayo revenue at $840 million for full-year 2026, surpassing $3 billion in 2027, and reaching $6.3 billion in 2028.
In plain terms = sales are underwhelming today, but the Street is betting on a very steep curve — more than a sevenfold increase within two years.
What is Foundayo's edge over Wegovy?
On weight-loss efficacy, oral Wegovy may hold a slight advantage.
Foundayo's core selling point is dosing flexibility — it can be taken at any time of day, with no fasting requirement and no water restriction. Wegovy has strict dosing rules.
This means → Foundayo is not playing the "lose more weight" card; it is playing the "easier to take, easier to stick with" card.
Whether that convenience translates into real market share is the key variable to watch.
Content is for reference only, not financial advice.